Promising immunotherapy: Highlighting cytokine-induced killer cells

J Cell Biochem. 2019 Jun;120(6):8863-8883. doi: 10.1002/jcb.28250. Epub 2018 Dec 16.

Abstract

For many years, cancer therapy has appeared to be a challenging issue for researchers and physicians. By the introduction of novel methods in immunotherapy, the prospect of cancer therapy even more explained than before. Cytokine-induced killer (CIK) cell-based immunotherapy demonstrated to have potentiality in improving clinical outcomes and relieving major side effects of standard treatment options. In addition, given the distinctive features such as high safety, low toxicity effects on healthy cells, numerous clinical trials conducted on CIK cells. Due to the shortcomings that observed in CIK cell immunotherapy alone, arising a tendency to make modifications (combined modality therapy or combination therapy) including the addition of various types of cytokines, genetic engineering, combination with immune checkpoints, and so on. In this review, we have tried to bring forth the latest immunotherapy methods and their overview. We have discussed the combination therapies with CIK cells and the conducted clinical trials. This helps the future studies to use integrated therapies with CIK cells as a promising treatment of many types of cancers.

Keywords: cancer; combined modality therapy; cytokine-induced killer cells; immunotherapy.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Cytokine-Induced Killer Cells / immunology
  • Cytokine-Induced Killer Cells / transplantation*
  • Genetic Engineering
  • Humans
  • Immunotherapy
  • Neoplasms / immunology
  • Neoplasms / therapy*